Search
for
Sort by
Research 451–480 of 1000+
- Real‐life effectiveness and safety of baricitinib in patients with severe alopecia areata: A 24‐week Italian study
- Tissue expansion and follicular unit extraction hair restoration in rehabilitation of a severe postburn deformity of neck and beard region
- Assessing a measure for Quality of Life in patients with severe Alopecia Areata: a multicentric Italian study
- LB1040 Machine learning-based predictive model with routine blood work identifies moderate-severe alopecia areata
- Case report: Sequential therapy with dupilumab and baricitinib for severe alopecia areata with atopic dermatitis in children
- JAK kinase pathway inhibitor drugs in patients with moderate-to-severe alopecia: a real-world experience
- Efficacy of tofacitinib as an induction agent in severe alopecia areata compared to oral betamethasone weekly pulse
- Comparative efficacy and safety of JAK inhibitors in the treatment of moderate-to-severe alopecia areata: a systematic review and network meta-analysis
- Baricitinib Demonstrates Rapid Action Within Just 2 Months of Treatment in Severe and Unresponsive Alopecia Areata: A Case Report
- Efficacy and Safety of Topical Corticosteroid Treatment under Occlusion for Severe Alopecia Areata in Children. A single-center retrospective analysis
- The effect of low-level laser therapy on severe acute respiratory syndrome coronavirus-2 infected cells
- Long‐term efficacy and safety of baricitinib in patients with severe alopecia areata: 104‐week results from BRAVE‐AA1 and BRAVE‐AA2
- Effectiveness and safety of baricitinib in patients with moderate‐to‐severe refractory alopecia areata in real world: An open‐label, single‐center study
- Distribution of SALT scores by Therapeutic Tesponse in Patients with Severe Alopecia After 52 weeks of Baricitinib Therapy
- Effectiveness of oral tofacitinib treatment on patients with moderate‐to‐severe alopecia areata in Iran
- <i>DSG4</i> Gene Variants as a Cause of Hypotrichosis in the Child with Severe Atopic Dermatitis: Clinical Case
- 164 Epigenetic and transcriptional profiling of PBMCs in mild and severe alopecia areata using single-cell RNA-Seq and ATAC-Seq
- THU471 Resolution Of Elevated Alkaline Phosphatase After Joint Replacement In Severe Osteoarthritis
- 43696 Early real-world experience with baricitinib in the treatment of severe alopecia areata
- 44047 Long Term Real-World Treat-to-Target Skin Clearance and Maintenance of Response with Risankizumab in Patients with Moderate to Severe Psoriasis From the CorEvitas Psoriasis Registry
- 43046 Outcomes of Down-Titration in Patients with Severe Scalp Alopecia Areata Treated with Baricitinib 4 Mg: Week 104 Data from BRAVE-AA2
- Efficacy of mesalazine in children with moderate to severe alopecia areata: case series of 18 patients
- Efficacy and Safety of Fractional CO2 Laser Combined with Halometasone Cream for Treatment of Moderate-to-Severe Chronic Hand Eczema: A Prospective, Single-Center, Parallel-Group, Open-Label Randomized Trial
- Diagnosis and differential diagnosis of tertiary androgenetic alopecia with severe alopecia areata based on high‐resolution MRI
- Diphenylcyclopropenone and platelet‐rich plasma in the management of severe or recalcitrant alopecia areata
- P64 Efficacy of baricitinib in patients with different degrees of severe alopecia areata: 52-week results from BRAVE-AA1 and BRAVE-AA2
- BH15 Efficacy and safety of baricitinib in the management of severe alopecia areata over a 6-month period: a real-world experience
- EE325 Budget Impact of Baricitinib for Patients with Severe Alopecia Areata
- Myxedema Coma and Acute Hepatopathy in a Dog with Severe Atherosclerosis
- Faculty Opinions recommendation of Identification of drug-specific public TCR driving severe cutaneous adverse reactions.